Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 501–600 of 1,026
Seliger, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122168 · Cited by 129
“The interaction of PD-1 with its ligands, PD-L1 and PD-L2, provides an immune escape for tumor cells due to inhibition of T cell activation and cytokine production leading to the attenuation of T cell responses by blocking proliferation, apoptosis induction and differentiation of regulatory T cells (Tregs) [4,5].”
BackgroundZhou, X., Zou, L., Liao, H., Luo, J., Yang, T., Wu, J., Chen, W., Wu, K., Cen, S., Lv, D., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.016 · Cited by 123
Strating, E., Verhagen, M. P., Wensink, G. E., Dünnebach, E., Wijler, L. A., Aranguren, I., la Cruz, A. S. D., Peters, N. A., Hageman, J. H., van der Net, M. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1053920 · Cited by 136
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Chiossone, L., Vienne, M., Kerdiles, Y. M., & Vivier, É. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.003 · Cited by 125
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
Hensler, M., Kašíková, L., Fišer, K., Raková, J., Škapa, P., Laco, J., Láníčková, T., Pecen, L., Truxová, I., Vosahlikova, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000979 · Cited by 117
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Mantuano, N. R., Natoli, M., Zippelius, A., & Laubli, H. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001222 · Cited by 127
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 135
“Tumors that lack immune cell infiltration and do not respond to ICIs are referred to as “cold tumors”, while tumors with high levels of immune cell infiltration and upregulated immune checkpoints that may respond to ICIs are referred as “hot tumors” [20].”
BackgroundScheffer, H. J., Stam, A. G. M., Geboers, B., Vroomen, L. G. P. H., Ruarus, A. H., de Bruijn, B., van den Tol, M. P., Kazemier, G., Meijerink, M. R., & de Gruijl, T. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652532 · Cited by 125
“Indeed, our finding of specific and transient upregulation of PD-1 levels on T cells provides a clear rationale for such a future combination therapy with PD-1 blockade in man.(23)”
BackgroundResultZhang, H., Liu, Z., Wen, H., Guo, Y., Xu, F., Zhu, Q., Yuan, W., Luo, R., Lu, C., Liu, R., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03173-w · Cited by 130
Wang, M. M., Coupland, S. E., Aittokallio, T. A., & Figueiredo, C. R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02361-4 · Cited by 123
“Cold tumours can be further divided into two subgroups: ‘desert’ tumours, which are deficient in generating anti-tumour T cells and have very few numbers of infiltrated T cells in the tumour stroma [9] (Fig.”
BackgroundMetabolic Reprogramming of Immune Cells in the Tumor Microenvironment
Wang, J., He, Y., Hu, F., Hu, C., Sun, Y., Yang, K., & Yang, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212223 · Cited by 147
Zhou, L., Lyu, J., Liu, F., Su, Y., Feng, L., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305361 · Cited by 134
Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies
Yasmeen, F., Pirzada, R. H., Ahmad, B., Choi, B., & Choi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147666 · Cited by 153
“This antigen presentation by mTECs to developing T-cells is crucial for the elimination of self-reactive CD4+ and CD8+ T-cells, ensuring central tolerance [47,48].”
BackgroundOrgan-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid, S., Diem, S., Li, Q., Krapf, M., Flatz, L., Leschka, S., Desbiolles, L. M., Klingbiel, D., Jochum, W., & Früh, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2239-4 · Cited by 118
Viitala, M., Virtakoivu, R., Tadayon, S., Rannikko, J., Jalkanen, S., & Hollmén, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3016 · Cited by 110
“For example, inhibiting PD-1/PD-L1 interaction in inflamed tumors can reactivate CD8þ T cells in the TME, sometimes leading to dramatic tumor regression, whereas noninflamed tumors are typically refractory to immune checkpoint blockade (4).”
BackgroundDirecting Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 152
“These cells must then traffic to the tumor site, infiltrate into the tumor bed, and finally recognize and kill tumor cells (9, 14).”
BackgroundKong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 136
Coagulome and the tumor microenvironment: an actionable interplay
Galmiche, A., Rak, J., Roumenina, L. T., & Saidak, Z. (2022) · Trends in cancer · doi:10.1016/j.trecan.2021.12.008 · Cited by 122
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 125
Zheng, Y., Sun, L., Guo, J., & Ma, J. (2023) · 癌症:英文版 · doi:10.1002/cac2.12487 · Cited by 125
“These include the inflamed type, immune-altered type, and immune-desert type [190–192].”
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Cervera-Carrascón, V., Siurala, M., Santos, J. M., Havunen, R., Tähtinen, S., Karell, P., Sorsa, S., Kanerva, A., & Hemminki, A. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1412902 · Cited by 120
“limitations of checkpoint blockade are situations where the tumor is invisible to the immune system (“cold” and “excluded” tumors),(8) or situations where immune suppression is exerted through several pathways concurrently.(9,10) It is increasingly appreciated that checkpoint inhibition tends to work in “hot” tumors c…”
BackgroundLi, B., Wang, Z., Wu, H., Xue, M., Lin, P., Wang, S., Lin, N., Huang, X., Pan, W., Liu, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3801 · Cited by 114
3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Modugno, F. D., Colosi, C., Trono, P., Antonacci, G., Ruocco, G., & Nisticò, P. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1086-2 · Cited by 121
“Details of the method and novel applications including RNA sequencing (RNASeq) and computational methods used to study immune cell changes in response to ex vivo ICB, have been reported in a subsequent publication where the Authors also discuss the limitations of the method [111].”
InfluentialAccolla, R. S., Ramia, E., Tedeschi, A., & Forlani, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01806 · Cited by 120
“an “inflamed or hot” tumor microenvironment, respectively (38, 39).”
BackgroundRole of cell surface proteoglycans in cancer immunotherapy
Espinoza‐Sánchez, N. A., & Götte, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.012 · Cited by 122
Li, X., Wang, X., Ito, A., & Tsuji, N. M. (2020) · Nature Communications · doi:10.1038/s41467-020-17637-z · Cited by 114
Feng, X., Lin, T., Chen, D., Li, Z., Yang, Q., Tian, H., Xiao, Y., Lin, M., Liang, M., Guo, W., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.02.011 · Cited by 117
Self-citationMitchell, K. A., Zingone, A., Toulabi, L., Boeckelman, J., & Ryan, B. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0527 · Cited by 117
“Cancer immunotherapies targeting immune checkpoint proteins have emerged in recent years as an effective cancer therapeutic (33).”
BackgroundKnapp, D. W., Dhawan, D., Ramos, J. A., Ratliff, T. L., Cresswell, G. M., Utturkar, S. M., Sommer, B. C., Fulkerson, C. M., & Hahn, N. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01493 · Cited by 137
Wang, C., Chiao, C.-C., Phan, N. N., Li, C.-Y., Sun, Z., Jiang, J., Hung, J., Chen, Y., Yen, M., Weng, T.-Y., et al. (2020) · PubMed Central · Cited by 124
The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability
Roy, A. M., Iyer, R. V., & Chakraborty, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101170 · Cited by 152
Verschueren, E., Husain, B., Yuen, K. C. Y., Sun, Y. E., Paduchuri, S., Şenbabaoğlu, Y., Lehoux, I. E., Arena, T. A., Wilson, B., Lianoglou, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.007 · Cited by 113
Humanized Rodent Models for Cancer Research
Tian, H., Lyu, Y., Yang, Y., & Hu, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01696 · Cited by 124
“It is widely accepted that the immune system is closely related to oncogenesis and cancer prognosis as well as response to anticancer therapies (7).”
BackgroundImmunotherapy in non-small cell lung cancer harbouring driver mutations
Addeo, A., Passaro, A., Malapelle, U., Banna, G. L., Subbiah, V., & Friedlaender, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102179 · Cited by 120
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
“Putting this tissue-independent TME classification into broader perspective, it may challenge the idea of cancer immunogram or cancer-related set-points, adding another brick to the wall of the concept of personalised medicine [52,96,97].”
BackgroundZhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
“Compared to hot tumors, the la t ter two phenotypes rare ly respond to ICB immunotherapy, which results in primary drug resistance (65).”
BackgroundSolinas, C., Garaud, S., De Silva, P., Boisson, A., Van den Eynden, G., de Wind, A., Risso, P., Rodrigues Vitória, J., Richard, F., Migliori, E., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01412 · Cited by 106
“This analysis was undertaken to (1) correlate their expression in the BC molecular subtypes; (2) associate specific BC cellular subpopulations with clinicopathological data; (3) situate their location in the tumor microenvironment; and (4) correlate their presence with BC prognosis.”
BackgroundRadioimmunotherapy for the treatment of head and neck cancer
Karam, S. D., & Raben, D. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30306-7 · Cited by 108
Guibert, N., Jones, G., Beeler, J. F., Plagnol, V., Morris, C., Mourlanette, J., Delaunay, M., Keller, L., Rouquette, I., Favre, G., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.005 · Cited by 106
Tong, H., Sun, J., Fang, J., Zhang, M., Liu, H., Xia, R., Zhou, W., Liu, K., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859323 · Cited by 126
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
“Tumors can be classified into “immune desert”, “immune exclusion”, and “inflammatory” categories based on the number of infiltrated CD8 + T lymphocytes [138, 139].”
BackgroundTrial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Yap suppresses T-cell function and infiltration in the tumor microenvironment
Stampouloglou, E., Cheng, N., Federico, A., Slaby, E., Monti, S., Szeto, G. L., & Varelas, X. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000591 · Cited by 104
Recent progress in tumor photodynamic immunotherapy
Shen, L., Zhou, T., Fan, Y., Chang, X., Wang, Y., Sun, J., Xing, L., & Jiang, H. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.02.007 · Cited by 105
Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
Huang, K. C., Chiang, S., Chen, W. T., Chen, T.-W., Hu, C., Yang, P.-C., Ke, T., & Chao, K. S. C. (2020) · Cancers · doi:10.3390/cancers12020462 · Cited by 105
“However, the majority of CRC patients do not respond to an immune checkpoint blockade (ICB), especially patients with microsatellite-stable (MSS) tumors [14–16].”
BackgroundSex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Conforti, F., Pala, L., Pagan, E., Bagnardi, V., Pas, T. M. D., Queirolo, P., Pennacchioli, E., Catania, C., Cocorocchio, E., Ferrucci, P. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0136 · Cited by 120
“It should be noted that although hypoxia is one of the most important features of the metabolic status of TME affecting immune response, a number of other elements of metabolism are implicated in the modulation of the immune system and may differ according to gender (33, 34, 36).”
BackgroundInfluentialMu, X., Zhang, M., Wei, A., Yin, F., Wang, Y., Hu, K., & Jiang, J. (2021) · Nanoscale · doi:10.1039/d0nr08024a · Cited by 105
Towards a consensus definition of immune exclusion in cancer
Tiwari, A., Oravecz, T., Dillon, L. A. L., Italiano, A., Audoly, L., Fridman, W. H., & Clifton, G. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084887 · Cited by 129
“Frontiers in Immunology 02 profiles (2, 4, 22).”
BackgroundInfluentialUltrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy
Ni, K., Lan, G., Chan, C., Duan, X., Guo, N., Veroneau, S. S., Weichselbaum, R. R., & Lin, W. (2019) · Matter · doi:10.1016/j.matt.2019.06.007 · Cited by 107
Kašíková, L., Raková, J., Hensler, M., Láníčková, T., Tománková, J., Pasulka, J., Drozenová, J., Mojžíšová, K., Fialová, A., Vosahlikova, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46873-w · Cited by 129
“While tumor-draining lymph nodes play a major role in the initiation of tumor-targeting immunity 12 , many solid neoplasms contain so-called “ tertiary lymphoid structures ” (TLSs), which in their mature form are spatially organized clusters of CD8 + effector T (T EFF ) cells, B lymphocytes, and…”
Solovyov, A., Vabret, N., Arora, K. S., Snyder, A., Funt, S. A., Bajorin, D. F., Rosenberg, J. E., Bhardwaj, N., Ting, D. T., & Greenbaum, B. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.042 · Cited by 102
“ERV Expression Can Be Associated with Positive AntiPD-L1 (CD274) Immunotherapy Response Pre-existing tumor T cell inflammation can be a strong predictor of response to cancer immunotherapy such as anti-PD-L1 (CD274)/PD-1 (PDCD1) or anti-CTLA-4 antibodies (Chen and Mellman, 2017).”
BackgroundmiR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer
Lou, Q., Liu, R., Yang, X., Li, W., Huang, L. J., Wei, L., Tan, H., Xiang, N., Chan, K., Chen, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0691-0 · Cited by 112
“Exploiting tumor cell-intrinsic checkpoint expression is revolutionizing cancer immunotherapy by inducing meaningful clinical responses in many cancer types; some examples of these therapies include targeting PD1 and PDL1 [5, 7].”
BackgroundBi, F., Chen, Y., & Yang, Q. F. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01472-9 · Cited by 104
“If abnormal proteins are finally recognized by immune cells, they will become neoantigens, and subsequent immune responses can develop [25].”
BackgroundHigh Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer
Vella, G., Guelfi, S., & Bergers, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736670 · Cited by 123
Huang, X., Pang, M.-J., Li, J.-Y., Chen, H., Sun, J., Song, Y., Ni, H.-J., Ye, S.-Y., Bai, S., Li, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36310-9 · Cited by 122
Lieber, S., Reinartz, S., Raifer, H., Finkernagel, F., Dreyer, T. F., Bronger, H., Jansen, J. M., Wagner, U. A. G., Worzfeld, T., Müller, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1424672 · Cited by 114
Immune Checkpoint Blockade for Breast Cancer
Swoboda, A., & Nanda, R. (2018) · Cancer Treatment and Research · doi:10.1007/978-3-319-70197-4_10 · Cited by 101
“Tumor immune evasion can occur as a result of the disruption of each of these three key T cell activities, resulting in three distinct cancer-immune phenotypes [2].”
BackgroundTray, N., Weber, J. S., & Adams, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0214 · Cited by 106
Decalf, J., Albert, M. L., & Ziai, J. (2019) · The Journal of Pathology · doi:10.1002/path.5223 · Cited by 101
Tian, Y., Zhai, X., Han, A., Zhu, H., & Yu, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0753-2 · Cited by 108
“As tumors develop, they can escape immune surveillance by various mechanisms in steps in the cancer-immunity cycle [19, 20].”
BackgroundZheng, B. J., Wang, D., Qiu, X., Luo, G., Wu, T., Yang, S., Li, Z., Zhu, Y., Wang, S., Wu, R. T., et al. (2020) · Advanced Science · doi:10.1002/advs.202000224 · Cited by 121
Erfani, A., Diaz, A. E., & Doyle, P. S. (2023) · Materials Today · doi:10.1016/j.mattod.2023.03.006 · Cited by 108
Castiglioni, A., Yang, Y., Williams, K., Gogineni, A., Lane, R. S., Wang, A. W., Shyer, J. A., Zhang, Z., Mittman, S., Gutierrez, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40398-4 · Cited by 116
“…framework of three tumor-immune phenotypes has been established based on histopathology: (I) in fl amed, in which CD8 T cells in fi ltrate the tumor parenchyma (II) excluded, in which CD8 T cells accumulate at the tumor – stroma boundary and (III) desert, in which CD8 T cells are mainly absent 2,3 .”
Self-citationRecruiting T cells in cancer immunotherapy
Yost, K. E., Chang, H. Y., & Satpathy, A. T. (2021) · Science · doi:10.1126/science.abd1329 · Cited by 109
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes
Colunga, A., Pulliam, T. H., & Nghiem, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0439 · Cited by 101
“In addition, mutation, adaptation, and selection for therapeutically resistant cells are remarkably powerful processes that continue to blunt therapeutic efficacy for all classes of drugs, including immunotherapy (68).”
BackgroundKalaora, S., Wolf, Y., Feferman, T., Barnea, E., Greenstein, E., Reshef, D., Tirosh, I., Reuben, A., Patkar, S., Levy, R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1418 · Cited by 105
“…c e u s e r on 07 A ugu s t 2023 www.aacrjournals.org (23), RNA vaccines (7, 8, 24), or other expansion protocols to select T-cell populations reactive against patient-specific antigens (5, 25), will greatly personalize this approach and potentially improve the effectiveness of the cancer therapy.”
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Cai, J., Qi, Q., Qian, X., Han, J. G., Zhu, X., Zhang, Q., & Xia, R. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02879-2 · Cited by 107
Cellular cytotoxicity is a form of immunogenic cell death
Minute, L., Teijeira, Á., Sánchez-Paulete, A. R., Ochoa, M. C., Álvarez, M., Otano, I., Etxeberría, I., Bolaños, E., Azpilikueta, A., Garasa, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000325 · Cited by 116
Zhou, Y., Bastian, I. N., Long, M. D., Dow, M., Li, W., Liu, T., Ngu, R. K., Antonucci, L., Huang, J. Y., Phung, Q. T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025840118 · Cited by 100
“Tumor-infiltrating CTLs, however, were strongly increased after anti – PD-L1 + Oxali treatment as indicated by scRNA-seq and flow cytometry.”
InfluentialSelf-citationProgramme of self-reactive innate-like T cell-mediated cancer immunity
Chou, C., Zhang, X., Krishna, C., Nixon, B. G., Dadi, S., Capistrano, K. J., Kansler, E. R., Steele, M., Han, J., Shyu, A., et al. (2022) · Nature · doi:10.1038/s41586-022-04632-1 · Cited by 110
Huang, W., Jiang, Y., Xiong, W., Sun, Z., Chen, C., Yuan, Q., Zhou, K., Han, Z., Feng, H., Chen, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32816-w · Cited by 111
In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer
Kather, J. N., Poleszczuk, J., Suarez-Carmona, M., Krisam, J., Charoentong, P., Valous, N. A., Weis, C.-A., Tavernar, L., Leiss, F., Herpel, E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2006 · Cited by 100
Immune checkpoint inhibitors for metastatic bladder cancer
Massari, F., Nunno, V. D., Cubelli, M., Santoni, M., Fiorentino, M., Montironi, R., Cheng, L., López-Beltrán, A., Battelli, N., & Ardizzoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.007 · Cited by 107
“There are several evidences showing that previously inflamed tumour could more benefit from immune-checkpoints inhibitors while “no-T cell inflamed tumours” not [24-26].”
BackgroundImaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy
Levi, J., Lam, T., Goth, S. R., Yaghoubi, S. S., Bates, J., Ren, G., Jivan, S., Huynh, T. L., Blecha, J. E., Khattri, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0267 · Cited by 107
Liu, Q., Fan, T., Zheng, Y., Yang, S., Yu, Z., Duo, Y., Zhang, Y., Adah, D., Shi, L., Sun, Z., et al. (2020) · Nanoscale · doi:10.1039/d0nr05953f · Cited by 100
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
Pu, D., Yin, L., Huang, L., Qin, C., Zhou, Y., Wu, Q., Li, Y., Zhou, Q., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637504 · Cited by 110
“A variety of combinations are in clinical trials, such as ICIs combined with GM-CSF, targeted drugs, oncolytic virus, chemotherapy, radiotherapy, IDO inhibitor, etc. (41, 42).”
BackgroundInfluentialFalcomatà, C., Bärthel, S., Widholz, S. A., Schneeweis, C., Montero, J. J., Toska, A., Mir, J., Kaltenbacher, T., Heetmeyer, J., Swietlik, J. J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-021-00326-1 · Cited by 109
Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy
Escriche‐Navarro, B., Escudero, A. C., Lucena‐Sánchez, E., Sancenón, F., García‐Fernández, A., & Martínez‐Máñez, R. (2022) · Advanced Science · doi:10.1002/advs.202200756 · Cited by 101
Fukui, T., Okuma, Y., Nakahara, Y., Otani, S., Igawa, S., Katagiri, M., Mitsufuji, H., Kubota, M., Hiyoshi, Y., Ishihara, M., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.021 · Cited by 105
Steenbrugge, J., Breyne, K., Demeyere, K., De Wever, O., Sanders, N. N., Van Den Broeck, W., Colpaert, C., Vermeulen, P., Van Laere, S., & Meyer, E. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0860-x · Cited by 99
Laheurte, C., Dosset, M., Vernerey, D., Boullerot, L., Gaugler, B., Gravelin, E., Kaulek, V., Jacquin, M., Cuche, L., Eberst, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0531-5 · Cited by 115
“NSCLC progression is associated with a decrease of functional anti-TERT Th1 response and accumulation of exhausted PD-1 /TIM-3 CD4 T cells The concept of cancer immune surveillance suggests that tumour progression is accompanied by an accumulation of immune escape factors, to the detriment of effector T-cell immunity.…”
BackgroundResultTumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights
Kumar, S., Singh, S. K., Rana, B., & Rana, A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.002 · Cited by 120
“The immune-desert TME is the immune-neglected region within the tumor that lacks functional effector T cells [11].”
BackgroundLiu, S., Zhang, Y., Liu, Y., Wang, W., Gao, S., Yuan, W., Sun, Z., Liu, L., & Wang, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02076-y · Cited by 111
“However, one of the biggest challenges of current CIT is the narrow range of patients and the remarkable individual differences, which may be attributed to the heterogeneity of the TME [6, 7].”
BackgroundAtherosclerosis With Immune Checkpoint Inhibitor Therapy
Suero‐Abreu, G. A., Zanni, M. V., & Neilan, T. G. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.11.011 · Cited by 107
Biomaterial‐Based In Situ Cancer Vaccines
Yang, B., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202210452 · Cited by 106
Zeng, D., Fang, Y., Qiu, W., Luo, P., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Wang, G., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100910 · Cited by 141
Orecchioni, S., Talarico, G., Labanca, V., Calleri, A., Mancuso, P., & Bertolini, F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0076-z · Cited by 98
Rouanne, M., Roumiguié, M., Houédé, N., Masson-Lecomte, A., Colin, P., Pignot, G., Larré, S., Xylinas, E. N., Rouprêt, M., & Neuzillet, Y. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2332-5 · Cited by 109
Ostmeyer, J., Christley, S., Toby, I. T., & Cowell, L. G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2292 · Cited by 105
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer
Borcoman, É., Rochère, P. D. L., Richer, W., Vacher, S., Chemlali, W., Krucker, C., Sirab, N., Radvanyi, F., Allory, Y., Pignot, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581556 · Cited by 97
Huang, R., Mao, M., Lu, Y., Yu, Q., & Liao, L. (2020) · Aging · doi:10.18632/aging.103054 · Cited by 123
“therapy especially during melanoma progression [19, 20].”
Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy
Bekeschus, S. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102798 · Cited by 108
“sized to support the activation of DCs to present tumor antigens for T-cell priming in draining lymph nodes to elicit the cancer-immunity cycle [178], as described in previous concepts [179].”
BackgroundSteele, K. E., Tan, T. H., Korn, R., Dacosta, K., Brown, C., Kuziora, M., Zimmermann, J., Laffin, B., Widmaier, M., Rognoni, L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0326-x · Cited by 97
“Numerous cancer studies have confirmed the importance of CD8 as a principal intratumoral marker of immune activity [4, 15].”
BackgroundDesigning natural and synthetic immune tissues
Gosselin, E. A., Eppler, H. B., Bromberg, J. S., & Jewell, C. M. (2018) · Nature Materials · doi:10.1038/s41563-018-0077-6 · Cited by 103
Jones, K. I., Tiersma, J. F., Yuzhalin, A. E., Gordon-Weeks, A. N., Buzzelli, J. N., Im, J. H., & Muschel, R. J. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809342 · Cited by 103
“The presence of T cells at the tumour core compared with tumour margins is associated with improved outcomes (Galon et al, 2006; Berthel et al, 2017; Chen & Mellman, 2017).”
BackgroundImaging of T-cells and their responses during anti-cancer immunotherapy
Krekorian, M., Fruhwirth, G. O., Srinivas, M., Figdor, C. G., Heskamp, S., Witney, T. H., & Aarntzen, E. H. J. G. (2019) · Theranostics · doi:10.7150/thno.37924 · Cited by 106
“In effective anti-cancer immune responses, tumour destruction and subsequent inflammation results in the induction of new waves of effector cells, thereby continuing the cancer-immunity cycle [15, 16].”
BackgroundKristensen, L. K., Fröhlich, C., Christensen, C. L., Melander, M. C., Poulsen, T. T., Galler, G. R., Lantto, J., Horak, I. D., Kragh, M., Nielsen, C. H., et al. (2019) · Theranostics · doi:10.7150/thno.37513 · Cited by 102
Song, K., Oh, S. J., Kim, S., Cho, H., Lee, H.-J., Song, J. S., Chung, J., Cho, E., Lee, J., Jeon, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14259-y · Cited by 105
Cancer Cell Coating Nanoparticles for Optimal Tumor-Specific Cytokine Delivery
Barberio, A. E., Smith, S. G., Correa, S., Nguyen, C., Nhan, B. T., Melo, M. B., Tokatlian, T., Suh, H., Irvine, D. J., & Hammond, P. T. (2020) · ACS Nano · doi:10.1021/acsnano.0c03109 · Cited by 99
Qi, J., Crinier, A., Escalière, B., Ye, Y., Wang, Z., Zhang, T., Batista, L., Liu, H., Hong, L., Wu, N., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100353 · Cited by 108
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.